Statins, Neuromuscular Degenerative Disease and an Amyotrophic Lateral Sclerosis-Like Syndrome

Edwards, I. Ralph; Star, Kristina; Kiuru, Anne

doi:10.2165/00002018-200730060-00005

Cited by 68 publications

(56 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In the first study, the WHO Foundation Collaborating Centre for International Drug Monitoring reported that upper neuron lesions appeared more often than expected in combination with statin medications, but such a disproportionality was not seen associating statins with Parkinson disease. 5 A similar signal was reported in the second study, which used the US Food and Drug Administration's Spontaneous Event Reporting System. 6 The authors of the second study also conducted a retrospective analysis of 41 statin trials, which did not reveal any increase in incidence of amyotrophic lateral sclerosis (ALS) in patients treated with statins compared with placebo.…”

supporting

confidence: 67%

“…Using this model, we estimated the relative risk we would expect to observe (RRЈ), assuming the 2 surveillance studies 5,6 provided accurate estimates of the true relative risk (RR), and assuming a valid bias model. All statistical analyses were completed using SAS software (version 9.2, SAS Institute, Cary, NC).…”

Section: Discussionmentioning

confidence: 99%

“…First, we specifically focused on the association between statins and ALS and drew conclusions from a much larger sample of ALS cases than available in any previous study. 5,6 Second, we were able to examine the association over a long induction period, allowing the analysis of the association between both recent and former user. Finally, nesting our analyses in a uniformly organized healthcare system allowed a population-based case-control design.…”

Section: Discussionmentioning

confidence: 99%

“…5,6 These surveillance data bases record adverse events potentially related to prescription drug use but are not population-based and reporting is not mandatory. In the first study, the WHO Foundation Collaborating Centre for International Drug Monitoring reported that upper neuron lesions appeared more often than expected in combination with statin medications, but such a disproportionality was not seen associating statins with Parkinson disease.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Statin Use and Risk of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Sørensen

Riis²,

Lash³

et al. 2010

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

Background-Use of statins has been associated with an amyotrophic lateral sclerosis-like syndrome in 2 analyses of overlapping surveillance databases that record adverse events potentially related to prescription drug use. We assessed whether statin use is associated with the occurrence of amyotrophic lateral sclerosis and other motor neuron disorders. Methods and Results-We conducted a population-based case-control study in Northern Denmark, with a population of 1.8 million. From the Danish National Registry of Patients, we identified incident cases coded with amyotrophic lateral sclerosis or other motor neuron syndromes during the period from 1999 to 2008. We selected 10 population control subjects matched to cases on sex, birth year, and calendar time. Statin use was ascertained in the prescription database in the region-and so recorded before diagnosis-and associated with disease occurrence by conditional logistic regression adjusting for covariates. We identified 556 cases of amyotrophic lateral sclerosis or other motor neuron syndromes and 5560 population control subjects. The odds ratio associating disease occurrence with statin use was 0.96 (95% confidence interval, 0.73 to 1.28). Recent users of statins, former users, and users of short or long duration had similarly near-null associations. Conclusions-Any

show abstract

supporting

confidence: 67%

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Statin Use and Risk of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Sørensen

Riis²,

Lash³

et al. 2010

Circ: Cardiovascular Quality and Outcomes

View full text Add to dashboard Cite

show abstract

“…Many disease processes have been suggested to be affected by statin use, including protection from infectious processes [5]; effects on cancer [6,7]; protection against dementia [8] and fractures [9]; effects on the eye [10,11] and a range of neurological [12,13] and immune-mediated diseases [14]. However, outside clinical trials, exposure to statins is not randomized, but is determined by a wide range of health-related factors.…”

Section: Introductionmentioning

confidence: 99%

Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials

Smeeth

Douglas

Hall

et al. 2008

Brit J Clinical Pharma

214

201

View full text Add to dashboard Cite

WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The effect of statins on cardiovascular outcomes is well established.• Effects on numerous other health outcomes have been claimed, but results have been inconsistent.• Previous observational studies may have been affected by selection bias and confounding. WHAT THIS STUDY ADDS• This study was larger and more statistically powerful than the combined total of data from all randomized trials of statins undertaken to date.• The validity of the study is supported by findings for vascular outcomes being comparable to those observed in large randomized controlled trials.• There was little evidence to support effects of statins beyond their established effects on cardiovascular disease. AIMSTo assess the effect of statins on a range of health outcomes. METHODSWe undertook a population-based cohort study to assess the effect of statins on a range of health outcomes using a propensity score-based method to control for differences between people prescribed and not prescribed statins. We validated our design by comparing our results for vascular outcomes with the effects established in large randomized trials. The study was based on the United Kingdom Health Improvement Network database that includes the computerized medical records of over four and a half million patients. RESULTSPeople who initiated treatment with a statin (n = 129 288) were compared with a matched sample of 600 241 people who did not initiate treatment, with a median follow-up period of 4.4 years. Statin use was not associated with an effect on a wide range of outcomes, including infections, fractures, venous thromboembolism, gastrointestinal haemorrhage, or on specific eye, neurological or autoimmune diseases. A protective effect against dementia was observed (hazard ratio 0.80, 99% confidence interval 0.68, 0.95). There was no effect on the risk of cancer even after Ն8 years of follow-up. The effect sizes for statins on vascular end-points and mortality were comparable to those observed in large randomized trials, suggesting bias and confounding had been well controlled for. CONCLUSIONSWe found little evidence to support wide-ranging effects of statins on health outcomes beyond their established beneficial effect on vascular disease.

show abstract

Manifestations of Drug Toxicity on Mitochondria in the Nervous System

Reynolds

2008

Drug‐Induced Mitochondrial Dysfunction

View full text Add to dashboard Cite

Statins, Neuromuscular Degenerative Disease and an Amyotrophic Lateral Sclerosis-Like Syndrome

Cited by 68 publications

References 15 publications

Statin Use and Risk of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Statin Use and Risk of Amyotrophic Lateral Sclerosis and Other Motor Neuron Disorders

Effect of statins on a wide range of health outcomes: a cohort study validated by comparison with randomized trials

Manifestations of Drug Toxicity on Mitochondria in the Nervous System

Contact Info

Product

Resources

About